Drug intelligence / Profile preview

RS-1653

Development stage: Preclinical
Modality: Small Molecules

Overview

RS-1653 is a novel small molecule belonging to the class of 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives. It functions as a dual monoamine oxidase (MAO) inhibitor, targeting both MAO-A and MAO-B. The inhibition is generally reversible, with a notable differential reversibility where MAO-B inhibition has a longer duration than MAO-A inhibition. This compound is being investigated for its potential therapeutic applications, particularly in the context of Parkinson's disease.

Targets

MAOA (Monoamine oxidase A)MAOB (Monoamine oxidase B)

Beyond the preview

Go deeper on RS-1653.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RS-1653.

Explore the full profile